ID   KCL034
AC   CVCL_A267
SY   KCL-034
DR   ISCR; 1888
DR   NIHhESC; NIHhESC-14-0268
DR   Wikidata; Q54899681
RX   PubMed=23161805;
RX   PubMed=25122690;
RX   PubMed=26607962;
RX   PubMed=27345810;
RX   PubMed=28445466;
WW   https://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
CC   Group: Clinical grade hESC cell line.
CC   From: King's College London; London; United Kingdom.
CC   Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0268.
CC   Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-54.
CC   HLA typing: A*11,29; B*44,51; C*16,04; DRB1*04:07,07 (PubMed=23161805).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Donor information: Embryo is sibling to that giving rise to KCL033 (Cellosaurus=CVCL_A266).
CC   Derived from site: In situ; Blastocyst; UBERON=UBERON_0000358.
CC   Cell type: Embryonic stem cell; CL=CL_0002322.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Blastocyst stage
CA   Embryonic stem cell
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 21
//
RX   PubMed=23161805; DOI=10.1002/emmm.201201973;
RA   Jacquet L., Stephenson E., Collins R., Patel H., Trussler J.,
RA   Al-Bedaery R., Renwick P., Ogilvie C.M., Vaughan R., Ilic D.;
RT   "Strategy for the creation of clinical grade hESC line banks that
RT   HLA-match a target population.";
RL   EMBO Mol. Med. 5:10-17(2013).
//
RX   PubMed=25122690; DOI=10.5966/sctm.2014-0015;
RA   Devito L.G., Petrova A., Miere C., Codognotto S., Blakely N., Lovatt A.,
RA   Ogilvie C.M., Khalaf Y., Ilic D.;
RT   "Cost-effective master cell bank validation of multiple clinical-grade
RT   human pluripotent stem cell lines from a single donor.";
RL   Stem Cells Transl. Med. 3:1116-1124(2014).
//
RX   PubMed=26607962; DOI=10.1038/srep17258;
RA   Canham M.A., Van Deusen A.L., Brison D.R., De Sousa P.A., Downie J.M.,
RA   Devito L.G., Hewitt Z.A., Ilic D., Kimber S.J., Moore H.D., Murray H.,
RA   Kunath T.;
RT   "The molecular karyotype of 25 clinical-grade human embryonic stem
RT   cell lines.";
RL   Sci. Rep. 5:17258-17258(2015).
//
RX   PubMed=27345810; DOI=10.1016/j.scr.2015.12.034;
RA   Devito L.G., Jacquet L., Petrova A., Miere C., Wood V., Kadeva N.,
RA   Cornwell G., Codognotto S., Stephenson E., Ilic D.;
RT   "Generation of KCL034 clinical grade human embryonic stem cell line.";
RL   Stem Cell Res. 16:184-188(2016).
//
RX   PubMed=28445466; DOI=10.1038/nature22312;
RA   Merkle F.T., Ghosh S., Kamitaki N., Mitchell J., Avior Y., Mello C.,
RA   Kashin S., Mekhoubad S., Ilic D., Charlton M., Saphier G.,
RA   Handsaker R.E., Genovese G., Bar S., Benvenisty N., McCarroll S.A.,
RA   Eggan K.C.;
RT   "Human pluripotent stem cells recurrently acquire and expand dominant
RT   negative P53 mutations.";
RL   Nature 545:229-233(2017).
//